within Pharmacolibrary.Drugs.ATC.L;

model L02AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 12.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02AA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ethinylestradiol is a synthetic derivative of estradiol, used primarily as an oral contraceptive in combination with progestins. It is widely used for birth control and in hormone replacement therapy. Ethinylestradiol is an approved and commonly prescribed medication today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult women after single oral dose.</p><h4>References</h4><ol><li><p>Moreira de Brito, C, et al., &amp; Cercato, C (2021). Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. <i>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</i> 17(4) 673–681. DOI:<a href=\"https://doi.org/10.1016/j.soard.2020.12.007\">10.1016/j.soard.2020.12.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33547015/\">https://pubmed.ncbi.nlm.nih.gov/33547015</a></p></li><li><p>Jordy, AB, et al., &amp; Bækdal, TA (2021). Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical pharmacokinetics</i> 60(9) 1171–1185. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00976-x\">10.1007/s40262-020-00976-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33782832/\">https://pubmed.ncbi.nlm.nih.gov/33782832</a></p></li><li><p>Battipaglia, C, et al., &amp; Grandi, G (2023). Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 871–879. DOI:<a href=\"https://doi.org/10.1080/17425255.2023.2279752\">10.1080/17425255.2023.2279752</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37942662/\">https://pubmed.ncbi.nlm.nih.gov/37942662</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02AA03;
